Hansa Biopharma has filed a patent for compositions containing therapeutic antibodies to increase their potency. The method involves administering an agent to reduce Fc receptor binding of endogenous serum antibodies, followed by a therapeutic antibody resistant to the agent, such as trastuzumab with specific glycoforms, for treating cancer. GlobalData’s report on Hansa Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hansa Biopharma AB - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hansa Biopharma, Peptide pharmacophores was a key innovation area identified from patents. Hansa Biopharma's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Increasing potency of therapeutic antibodies for treating cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Hansa Biopharma AB

A recently filed patent (Publication Number: US20230398212A1) outlines a method for treating cancer in a subject by administering an agent called EndoS to reduce Fc receptor binding of endogenous serum antibodies. Following this, a therapeutic antibody, trastuzumab, is administered after a specified time interval. The therapeutic antibody is designed to include glycoforms resistant to the agent's activity in the Fc domain, specifically comprising oligomannose-type glycans. This method aims to enhance the effectiveness of the therapeutic antibody in treating various types of cancer.

The patent claims specify that the method can be applied to a range of cancers such as bladder cancer, lung cancer, breast cancer, melanoma, colon cancer, and others. The set time interval for administering the therapeutic antibody ranges from 1-2 days to 1-20 days. Additionally, the glycoforms in the Fc domain of the therapeutic antibody must contain at least 5 mannose residues, with specific configurations outlined in the claims. Notably, the method is particularly highlighted for the treatment of breast cancer, showcasing its potential impact in addressing this specific type of cancer. Overall, the patent presents a novel approach to cancer treatment by combining the use of specific agents and therapeutic antibodies to enhance their efficacy in combating cancer cells.

To know more about GlobalData’s detailed insights on Hansa Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies